Tuesday, 3 December 2013

Sanofi Announces New Phase 3 Results for Investigational New Insulin U300

We are encouraged by these results which suggest that U300 could be a viable treatment option for a wide range of people with type 1 and type 2 diabetes (Sanofi)

No comments:

Post a Comment